Headlands Technologies LLC Sells 3,915 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Headlands Technologies LLC lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 67.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,922 shares of the company's stock after selling 3,915 shares during the quarter. Headlands Technologies LLC's holdings in Neurocrine Biosciences were worth $213,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Dodge & Cox grew its position in shares of Neurocrine Biosciences by 134.2% in the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock valued at $411,742,000 after purchasing an additional 1,728,605 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Neurocrine Biosciences by 2.9% in the fourth quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock valued at $258,926,000 after purchasing an additional 53,610 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Neurocrine Biosciences by 19.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,070,096 shares of the company's stock valued at $146,068,000 after purchasing an additional 175,879 shares during the last quarter. Northern Trust Corp grew its position in shares of Neurocrine Biosciences by 27.3% in the fourth quarter. Northern Trust Corp now owns 981,939 shares of the company's stock valued at $134,035,000 after purchasing an additional 210,315 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Neurocrine Biosciences by 8.6% in the fourth quarter. Invesco Ltd. now owns 949,512 shares of the company's stock valued at $129,608,000 after purchasing an additional 74,847 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on NBIX. Evercore ISI decreased their target price on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. UBS Group upped their target price on Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a research report on Wednesday, July 9th. HC Wainwright reduced their price target on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Stifel Nicolaus increased their price target on Neurocrine Biosciences from $166.00 to $174.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Finally, Canaccord Genuity Group increased their price target on Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $160.90.

Insiders Place Their Bets

In other news, Director Kevin Charles Gorman sold 106,322 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $126.41, for a total value of $13,440,164.02. Following the transaction, the director owned 514,596 shares of the company's stock, valued at approximately $65,050,080.36. This represents a 17.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jude Onyia sold 59,819 shares of the company's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the completion of the transaction, the insider directly owned 18,289 shares in the company, valued at approximately $2,385,982.94. The trade was a 76.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 196,573 shares of company stock worth $25,112,766 over the last 90 days. Corporate insiders own 4.80% of the company's stock.

Neurocrine Biosciences Stock Up 0.4%

Neurocrine Biosciences stock traded up $0.53 during trading on Friday, hitting $131.84. The stock had a trading volume of 75,908 shares, compared to its average volume of 1,274,945. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $154.87. The stock's 50 day moving average is $129.06 and its two-hundred day moving average is $119.95. The stock has a market cap of $13.08 billion, a price-to-earnings ratio of 39.00, a price-to-earnings-growth ratio of 0.95 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.08. The firm had revenue of $687.50 million for the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The business's quarterly revenue was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.63 earnings per share. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.